About Venn therapeutics

About company

Venn Therapeutics, a privately held immuno-oncology company focused on developing novel, early-stage cancer therapies, announced today that Dr. Stefani Spranger, Assistant Professor, Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, has been appointed to its scientific advisory board.